PPARG and pulmonary arterial hypertension: Since BMPR2 (17) and PPARγ (18) both guard against the development of PAH (19, 20), we hypothesized that loss of DLL4/NOTCH signaling might result in pulmonary hypertension through interactions with BMPR2 and PPARγ.